Skip to main content

LL-37 (Cathelicidin) Dosage Guide

50/100 confidence

Complete guide to LL-37 (Cathelicidin) dosing protocols, administration methods, and safety considerations for research purposes.

NOT Medical Advice

The dosage and calculator information provided is for educational and research purposes only. Peptides are not approved by the FDA for human use. Individual responses vary significantly. Always consult with a qualified healthcare professional before making any decisions related to peptide research or use.

Dosage Overview

Dose Range

500 mcg - 2 mg

Route

multiple

Frequency

2x daily

Detailed Dosage Information

Research protocols vary widely. Typical ranges: 50-200mcg administered subcutaneously 2-3 times weekly. Some protocols use higher doses for acute infections.

Administration Method

Subcutaneous injection. Can cause significant injection site reactions. Often used in conjunction with other immune-supporting protocols.

Research Backing

Wound-healing RCTs and antimicrobial studies; Phase I/II topical trials for venous ulcers and diabetic wounds.

Side Effects to Monitor

Injection site pain and reactions are common. May cause flu-like symptoms, temporary fatigue, or immune activation responses.

Safety Considerations & Risks

May overstimulate immune system in autoimmune conditions. Limited human research data. Quality and purity concerns with research products.